Surveillance study of the prevalence, species distribution, antifungal susceptibility, risk factors and mortality of invasive candidiasis in a tertiary teaching hospital in Southwest China

Zhang-rui Zeng†, Gang Tian†, Yin-huan Ding, Kui Yang, Jin-bo Liu and Jian Deng* 

Abstract

Background: Invasive candidiasis (IC) is the most common invasive fungal infection. The epidemiology of IC in hospitalized patients has been widely investigated in many metropolitan cities; however, little information from medium and small cities is known.

Methods: A 5-year retrospective study was carried out to analyze the prevalence, species distribution, antifungal susceptibility, risk factors and mortality of inpatients with invasive Candida infection in a regional tertiary teaching hospital in Southwest China.

Results: A total of 243 inpatients with invasive Candida infection during the five-year study period were identified, with a mean annual incidence of 0.41 cases per 1000 admissions and a 30-day mortality rate of 12.3%. The species distributions of Candida albicans, Candida glabrata, Candida tropicalis, Candida krusei, Candida parapsilosis and other Candida species was 45.3, 30.0, 15.2, 4.9, 2.1 and 2.5%, respectively. The total resistance rates of fluconazole (FCA), itraconazole (ITR) and voriconazole (VRC) were 18.6, 23.1 and 18.5%, respectively. Respiratory dysfunction, pulmonary infection, cardiovascular disease, chronic/acute renal failure, mechanical ventilation, abdominal surgery, intensive care in adults, septic shock and IC due to C. albicans were associated with 30-day mortality (P < 0.05) according to the univariate analyses. Respiratory dysfunction [odds ratio (OR), 9.80; 95% confidence interval (CI), 3.24–29.63; P < 0.001] and IC due to C. albicans (OR, 3.35; 95% CI, 1.13–9.92; P = 0.029) were the independent predictors of 30-day mortality.

Conclusions: This report shows that the incidence and mortality rates are lower and that the resistance rates to azoles are higher in medium and small cities than in large cities and that the species distributions and risk factors in medium and small cities are different from those in large cities in China. It is necessary to conduct epidemiological surveillance in medium and small cities to provide reference data for the surveillance of inpatients with IC infections.

Keywords: Invasive candidiasis, Epidemiology, Antifungal susceptibility, Mortality, Risk factors
Background
Invasive candidiasis (IC) is the most common fungal disease among hospitalized patients worldwide. According to conservative estimates, IC affects more than 250,000 people worldwide every year and is the cause of more than 50,000 deaths [1]. IC is widely reported in critically ill patients in the intensive care unit (ICU) [2]. The risk factors for IC included granulocytopenia, stem cell transplant, organ transplants, broad-spectrum antimicrobial agents, central venous catheterization, total parenteral nutrition, length of stay in the ICU, surgery, advanced life support, and aggressive chemotherapy [2]. With the increase of in related research, there have been reports showing that older age (over 65 years) [3], diabetes mellitus and chronic renal failure [4] are identified as risk factors for patients with IC.

IC is caused by Candida species and comprises both candidemia and deep-seated tissue candidiasis. Candidemia is the most frequent form of IC. More than 15 Candida species can cause human candidemia [1, 2]. Deep-seated candidiasis is caused by either hematogenous dissemination or the direct inoculation of Candida species to a sterile site, such as the peritoneal cavity. Globally, Candida albicans is the primary cause of candidemia and one of the most common species in many countries, including Japan (39.5%) [5], Italy (61.2%) [6], Russia (43.2%) [7], Saudi Arabia (38.3%) [8] and Mexico (40%) [9], among others. However, Candida parapsilosis (17.8%) is the most common cause of IC in Pakistan [10]. The global incidence of IC varies from 0.3 to 5 per 1000 admissions according to hospital-based studies [11]. The mortality rate of IC in immunocompromised and other critically ill patients is between 35 and 80% [12]. The cost of IC treatment reached US$ 17,000 per patient in China, which was significantly higher than that for patients without IC (US$ 8500; P = 0.001) [13].

In China, the epidemiology of IC varies widely among different areas [14]. C. albicans (44.9%) is the most common strain isolated from IC patients in China, particularly in metropolitan cities [15]. Non-C. albicans species (59.9%) also play an important role in IC [16]. Data regarding epidemiologic trends and patient susceptibility to invasive fungal infections has mainly been studied in metropolitan cities, and little information from medium and small cities is known. Therefore, in the present study, we performed a five-year retrospective study to evaluate the epidemiology, antifungal susceptibility, risk factors and mortality of IC in patients in a tertiary teaching hospital in Southwest China.

Methods
Patient data collection
We conducted a retrospective observational study of electronic laboratory records. The fungal specimen data were collected from inpatients who were aged > 16 years with IC in the Affiliated Hospital of Southwest Medical University (Luzhou, China), which is a 3200-bed tertiary care teaching hospital with 43 wards and approximately 120,000 annual admissions, from January 2013 to December 2017. The diagnostic criteria of IC were based on the guidelines for the diagnosis and treatment and the Chinese expert consensus statement issued by relevant societies and organizations of the Chinese Medical Association [17–19]; these criteria were also in accordance with the revised definitions of invasive fungal disease (IFD) from the European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) consensus group [20] and Infectious Diseases Society of America (IDSA) Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Bloodstream Infection [21]. For each patient, only the first episode was included in our analysis. Patient cultures with two or more fungal species were excluded from the analysis, and all data were collected from electronic medical records. The following data were retrospectively collected from all the patients: demographic characteristics, underlying comorbidities, specific fungal pathogens and species, susceptibility to antifungal agents and survival. The following risk factors associated with IC were also collected: systemic corticosteroid treatment (a dose equivalent to prednisone 10 mg/d for at least 14 days), neutropenia (absolute neutrophil count < 500 cells/μl), abdominal surgery, indwelling central vascular catheter, mechanical ventilation, ICU hospitalization, concomitant bacterial infections, chemotherapy, total parenteral nutrition, septic shock, hemodialysis, broad-spectrum antibiotic therapy and treatment with antifungal agents. Early mortality was defined as death within 7 days, and late mortality was defined as death between 7 and 30 days. The study protocol was approved by the ethics committee of the hospital (Project No. K2016004). The need for informed consent was waived by the Clinical Research Ethics Committee.

Microorganism identification and antifungal susceptibility
According to the manufacturer’s instructions, blood and sterile body fluid (including ascitic fluid, pleural fluid, cerebrospinal fluid and drainage fluid) were inoculated into both aerobic and anaerobic BacT/AlerT 3D vials (Bruker Diagnostics Inc., USA). The central venous catheter tips and sterile tissues were inoculated onto blood agar media (Columbia) and chocolate blood agar plates (+vancomycin) (Thermo Fisher Biochemical Product Co., Ltd., Beijing, China), respectively. All positive cultures were manually sampled and inoculated onto CHROMagar Candida medium (CHROMagar Company, France) to ensure viability and purity. The
identification of all species was confirmed by a MicroScan WalkAway 96 Plus System (Siemens, Germany) and Microflex LT (Bruker Diagnostics Inc., USA) matrix-assisted laser-desorption/ionization time-of-flight (MALDI-TOF) mass spectroscopy (MS) system.

Antifungal susceptibility tests for fluconazole (FCA), itraconazole (ITR), amphotericin B (AMB), voriconazole (VRC) and flucytosine (5-FC), were performed for all Candida strain isolates by using an ATB FUNGUS 3 kit (bioMérieux, France). The minimal inhibitory concentrations (MICs) of the antifungal agents were judged by visual reading in our laboratory according to the manufacturer’s instructions. The quality control strains were C. parapsilosis ATCC 22019 and C. krusei ATCC 6258. The results were interpreted using the Clinical and Laboratory Standards Institute M27-A3 microbroth dilution method.

Statistical analyses
The data were analyzed using SPSS software version 22 for Windows (SPSS, Chicago, IL, USA). The categorical data were compared using chi-square or Fisher’s exact tests. The continuous data were analyzed using Student’s t-test or Mann-Whitney U test. Statistical significance was determined using two-tailed tests, and P < 0.05 was considered statistically significant. Multivariable logistic regression analysis was performed to identify independent predictors of IC and 30-day hospital mortality. Biologically plausible variables with a value of P < 0.1 according to the univariate analyses were included in the multiple logistic regression model. For the independent predictors of 30-day hospital mortality, the following variables were entered into the model: respiratory dysfunction, pulmonary infection, cardiovascular disease, neurological diseases, chronic/acute liver disease, chronic/acute renal failure, mechanical ventilation, total parenteral nutrition, abdominal surgery, intensive care in adults, concomitant bacterial infections, septic shock, and C. albicans.

Results
A total of 243 distinct IC episodes were identified during our study period. The mean annual incidence of IC was 0.41/1000 admissions. A total of 209,611 cultures were also collected in our hospital; the positive rate of the fungal cultures was 4.3% (8963), 2.7% (243) of which corresponded to IC episodes from 21 wards. The culture-positive specimen came from the blood (116, 47.7%), sterile body fluid (98, 40.3%), central venous catheter tips (17, 7.0%) and sterile tissues (12, 4.9%). We classified all the wards into ICUs (42, 17.3%), medical wards (103, 40.3%) and surgical wards (98, 42.4%). C. albicans was the predominant species in the ICU and surgical wards (50.0 and 51.5%, respectively), whereas C. glabrata was the predominant species (41.8%) in the medical wards (Fig. 1).

The cohort characteristics are described in Table 1; among the included patients (median age, 60 years), 57.2% were males. The percentages of the three most common isolated Candida species were as follows: C. albicans (45.3%), C. glabrata (30.0%) and C. tropicalis (15.2%) (Table

![Fig. 1](image)

Distribution of the fungal species according to different wards. Others: C. guilliermondii (3), C. haemulonii (2) and C. pseudotropicalis (1)
Table 1 Patient characteristics and incidence (episode/1000 admission)

| Candida species | Total | C. albicans | C. glabrata | C. tropicalis | C. krusei | C. parapsilosis | Others |
|-----------------|-------|-------------|-------------|---------------|-----------|-----------------|--------|
|                 | (n = 243) | (n = 110) | (n = 73) | (n = 37) | (n = 12) | (n = 5) | (n = 6) |
| Patient characterisitics | 100.0% | 45.3% | 30.0% | 15.2% | 4.9% | 2.1% | 2.5% |
| Age (years) | | | | | | | |
| 16–49 | 70 (28.8) | 32 (45.7) | 23 (32.8) | 8 (11.4) | 3 (4.3) | 2 (2.9) | 2 (2.9) |
| 50–65 | 84 (34.6) | 24 (28.6) | 35 (41.6) | 15 (17.9) | 6 (7.1) | 2 (2.4) | 2 (2.4) |
| >65 | 89 (36.6) | 54 (60.7) | 15 (16.9) | 14 (15.7) | 3 (3.4) | 1 (1.1) | 2 (2.2) |
| Gender | | | | | | | |
| Male | 139 (57.2) | 60 (43.2) | 41 (29.5) | 28 (20.1) | 4 (2.9) | 4 (2.9) | 2 (1.4) |
| Female | 104 (42.8) | 50 (48.1) | 32 (30.8) | 9 (8.7) | 8 (7.7) | 1 (0.9) | 4 (3.8) |
| Underlying comorbidities (n,%) | | | | | | | |
| Gastrointestinal perforation | 48 (19.6) | 24 (50.0) | 10 (20.8) | 8 (16.7) | 5 (10.4) | 0 (0) | 1 (2.1) |
| Respiratory dysfunction | 51 (21.0) | 25 (49.0) | 16 (31.4) | 9 (17.6) | 0 (0) | 0 (0) | 1 (2.0) |
| Pulmonary infection | 81 (33.3) | 43 (53.1) | 20 (24.7) | 14 (17.3) | 1 (1.2) | 1 (1.2) | 2 (2.5) |
| Cardiovascular disease | 78 (32.1) | 41 (52.6) | 20 (25.6) | 10 (12.8) | 5 (6.4) | 0 (0) | 2 (2.6) |
| Neurological diseases | 58 (23.9) | 35 (60.4) | 10 (17.2) | 9 (15.5) | 2 (3.5) | 1 (1.7) | 1 (1.7) |
| Gastrointestinal pathology | 63 (25.9) | 32 (50.8) | 18 (28.6) | 7 (11.1) | 5 (7.9) | 1 (1.6) | 0 (0) |
| Chronic/acute liver disease | 45 (18.5) | 22 (48.9) | 9 (20.2) | 10 (22.2) | 3 (6.7) | 1 (2.2) | 0 (0) |
| Chronic/acute renal failure | 90 (37.0) | 48 (53.3) | 23 (25.6) | 15 (16.7) | 2 (2.2) | 0 (0) | 2 (2.2) |
| Solid tumour | 22 (9.1) | 11 (50.0) | 2 (9.1) | 7 (31.8) | 2 (9.1) | 0 (0) | 0 (0) |
| Haematological malignancy | 6 (2.5) | 3 (50.0) | 1 (16.7) | 1 (16.7) | 0 (0) | 0 (0) | 1 (16.6) |
| Severe autoimmune diseases | 11 (4.5) | 7 (63.6) | 0 (0) | 3 (27.3) | 1 (9.1) | 0 (0) | 0 (0) |
| Diabetes mellitus | 93 (38.3) | 57 (61.3) | 19 (20.4) | 11 (11.8) | 6 (6.5) | 0 (0) | 0 (0) |
| Burns | 6 (2.5) | 2 (33.3) | 1 (16.7) | 1 (16.7) | 0 (0) | 2 (33.3) | 0 (0) |
| HIV/AIDS | 13 (5.3) | 2 (15.4) | 10 (76.9) | 0 (0) | 0 (0) | 0 (0) | 1 (7.7) |
| Severe trauma | 15 (6.2) | 6 (40.0) | 3 (20.0) | 4 (26.6) | 1 (6.7) | 1 (6.7) | 0 (0) |
| Risk factors (n,%) | | | | | | | |
| Presence of CVC | 118 (48.6) | 59 (50.0) | 23 (19.5) | 24 (20.3) | 8 (6.8) | 2 (1.7) | 2 (1.7) |
| Mechanical ventilation | 82 (33.7) | 41 (50.0) | 19 (23.2) | 15 (18.3) | 5 (6.1) | 1 (1.2) | 1 (1.2) |
| Receipt of corticosteroids | 70 (28.8) | 43 (61.4) | 12 (17.1) | 14 (20.0) | 1 (1.4) | 0 (0) | 0 (0) |
| Total parenteral nutrition | 119 (49.0) | 62 (52.1) | 29 (24.4) | 19 (16.0) | 7 (5.9) | 1 (0.8) | 1 (0.8) |
| Chemotherapy | 11 (4.5) | 4 (36.4) | 1 (9.1) | 5 (45.4) | 1 (9.1) | 0 (0) | 0 (0) |
| Abdominal surgery | 69 (28.4) | 26 (37.7) | 27 (39.1) | 10 (14.5) | 4 (5.8) | 0 (0) | 2 (2.9) |
| Intensive care in adults | 42 (17.3) | 21 (50.0) | 9 (21.4) | 8 (19.0) | 2 (4.8) | 1 (2.4) | 1 (2.4) |
| Neutropenia | 7 (2.9) | 4 (57.1) | 0 (0) | 1 (14.3) | 2 (28.6) | 0 (0) | 0 (0) |
| Concomitant bacterial infections | 81 (33.3) | 46 (56.8) | 13 (16.0) | 18 (22.3) | 2 (2.5) | 1 (1.2) | 1 (1.2) |
| Septic shock | 46 (18.9) | 16 (34.8) | 19 (41.4) | 7 (15.2) | 2 (4.3) | 0 (0) | 2 (4.3) |
| Dialysis | 25 (10.3) | 9 (36.0) | 13 (52.0) | 2 (8.0) | 0 (0) | 0 (0) | 1 (4.0) |
| Previous antibiotics therapy | 215 (88.5) | 103 (47.9) | 60 (27.9) | 35 (16.3) | 12 (5.6) | 1 (0.5) | 4 (1.8) |
| Treatment with antifungal agents | 83 (34.2) | 44 (53.0) | 20 (24.1) | 14 (16.9) | 3 (3.6) | 0 (0) | 2 (2.4) |
| Incidence (episodes/1000 admissions) | | | | | | | |
| 2013 | 0.16 | 0.05 | 0.06 | 0.03 | 0.01 | 0 | 0.01 |
| 2014 | 0.31 | 0.16 | 0.07 | 0.06 | 0.01 | 0 | 0.01 |
| 2015 | 0.43 | 0.18 | 0.13 | 0.06 | 0.04 | 0.02 | 0 |
1). In patients in the age range of 49–65 years, *C. glabrata* was the predominant species (41.6%), but in patients in the age ranges of 16–49 and > 65, *C. albicans* was the main species (45.7 and 60.7%, respectively). The causative organism varied according to the age of the patients and their underlying diseases. With increasing age, the percentage of *C. glabrata* was reduced from 41.6 to 16.9%, and *C. albicans* and *C. tropicalis* significantly increased from 28.6 to 60.7% and from 11.4 to 15.7%, respectively. Non-*C. albicans* species were isolated with the highest frequency from patients with HIV/AIDS (84.6%); *C. glabrata* was the predominant species (76.9%). The incidence of IC increased from 0.16 episodes/1000 admissions in 2013 to 0.66 episodes in 2017, and the change in incidence over time was statistically significant (*P* < 0.05). A significant increase in the incidence (episodes/1000 admissions) of *C. albicans* (from 0.05 to 0.25), *C. glabrata* (from 0.06 to 0.23), *C. tropicalis* (from 0.03 to 0.12) and *C. parapsilosis* (from 0 to 0.03) was observed. The demographic and clinical characteristics of the patients are summarized in Table 1. Most of the patients had one or more comorbidities. The most common underlying comorbidities documented prior to IC were diabetes mellitus (38.3%), chronic/acute renal failure (37.0%), pulmonary infection (33.3%), cardiovascular disease (32.1%) and gastrointestinal pathology (25.9%). Moreover, the most common underlying conditions documented prior to IC were prior exposure to broad-spectrum antibiotics (88.5%), total parenteral nutrition (49.0%), central venous catheterization (48.6%), treatment with antifungal agents (37.6%) and mechanical ventilation (33.7%).

The results of in vitro susceptibility testing of the *Candida* strain isolates are summarized in Table 2. Among the *Candida* strains, AMB demonstrated excellent in vitro activity against all *Candida* species. All *Candida* strains (100%) were susceptible to AMB, while 95.9% of the isolates were susceptible to 5-FC. The resistance rate of ITR was the highest in the *Candida* species (23.1%). A total of 18.6% of the isolates were resistant to FCA. VRC resistance was observed in 18.5% of all the *Candida* isolates evaluated. The resistance rate of *C. tropicalis* was the highest among the *Candida* species; most of the isolates were resistant to FCA (29.7%), ITR (40.5%) and VRC (27.0%). The percentages of yeast isolates with resistance and decreased susceptibility to FCA, ITR and VRC were significantly decreased during the 5 years of observation. (Fig. 2).

The outcome data at day 30 were available for 243 episodes. The hospital mortality rate was 12.3%. The mortality rates among *C. albicans*, *C. glabrata*, *C. tropicalis* and *Candida haemulonii* infections were 18.2% (20 out of 110 patients), 8.2% (6 out of 73 patients), 8.1% (3 out of 37 patients) and 50.0% (1 out of 2 patients), respectively. Sixteen patients died within 7 days of obtaining a positive culture. Respiratory dysfunction (39.2%), intensive care in adults (28.5%), neutropenia (28.6%), severe autoimmune diseases (27.3%) and cardiovascular diseases (25.6%) were frequently associated with mortality during the study period.

The univariate predictors of poor outcomes due to IC are shown in Table 3. For patients with IC, the variables associated with 30-day mortality were as follows: respiratory dysfunction, pulmonary infection, cardiovascular disease, chronic/acute renal failure, mechanical ventilation, abdominal surgery, intensive care in adults, septic shock and IC due to *C. albicans*. The results of the multivariate analysis are listed in Table 4. Respiratory dysfunction [odds ratio (OR), 9.80; 95% confidence interval (CI), 3.24–29.63; *P* < 0.001] and IC due to *C. albicans* (OR, 3.35; 95% CI, 1.13–9.92; *P* = 0.029) were the independent predictors of 30-day mortality.

**Table 1** Patient characteristics and incidence (episode/1000 admission) (Continued)

| Year | Total | *C. albicans* | *C. glabrata* | *C. tropicalis* | *C. krusei* | *C. parapsilosis* | Others  |
|------|-------|---------------|--------------|---------------|-----------|-----------------|---------|
|      | (n = 243) | (n = 110) | (n = 73) | (n = 37) | (n = 12) | (n = 5) | (n = 6) |
| 2016 | 0.52   | 0.28          | 0.13         | 0.05          | 0.03      | 0.00            | 0.03    |
| 2017 | 0.66   | 0.25          | 0.23         | 0.12          | 0.02      | 0.03            | 0.01    |

*Includes the following diseases: chronic obstructive pulmonary disease and acute respiratory distress syndrome*

*Includes the following diseases: cholecystitis, pancreatitis, and peritonitis*

*Chronic/Acute renal failure is the permanent or sudden and often temporary loss of kidney function with N waste retention and hypourcinria*

*CVC central venous catheter*

*a dose equivalent to the prednisone dosage of 0.3 mg/kg/day for at least 14 days*

*Including: gastrointestinal perforations, severe acute pancreatitis and complex ventral hernia*

*Neutropenia is the absolute neutrophil count, that is, < 500 cells/μl*

*Others include: *C. guilliermondii* (3), *C. haemulonii* (2) and *C. pseudotropicalis* (1)
with the new standard for city-size classification in China (http://www.gov.cn/zhengce/content/2014-11/20/content_9225.htm). The urban population proportion, gross domestic product, income of residents, educational resources, sports resources, medical resources and air pollution in medium and small cities are less than those in large cities [23–25]; all the data are illustrated in the Additional file 1: Table S1.

Our data showed that the incidence of invasive Candida infection has increased steadily from 0.16 to 0.66 cases per 1000 admissions, which is similar to a metropolitan-based report in Beijing (0.13 to 0.55 cases

### Table 2 In vitro antifungal susceptibility testing of 243 clinical isolates into 5 antifungal agents

| Species              | Antifungal agent | MIC (μg/mL) | % Resistant | Range   | 50%  | 90%  |
|----------------------|------------------|-------------|-------------|---------|------|------|
| Candida albicans (110) | Amphotericin B    | ≤0.5 to 1   | ≤0.5        | ≤0.5   | 0    | 0    |
|                      | Flucytosine       | 0.5 to > 8  | 0.5         | 1       | 5.5  |
|                      | Fluconazole       | ≤0.125 to 32| 0.25        | 0.5     | 20.0 |
|                      | Itraconazole      | ≤0.062 to 4 | ≤0.062      | 0.5     | 28.2 |
|                      | Voriconazole      | ≤0.062 to > 8| ≤0.062     | 0.125   | 23.6 |
| Candida glabrata (73) | Amphotericin B    | ≤0.5 to 1   | ≤0.5        | 1       | 0    |
|                      | Flucytosine       | ≤0.062 to > 16| 0.125    | 0.5     | 2.7  |
|                      | Fluconazole       | 0.25 to > 128| 8        | 32      | 11.0 |
|                      | Itraconazole      | ≤0.25 to > 8| 2         | 4       | 6.8  |
|                      | Voriconazole      | ≤0.062 to > 8| ≤0.25    | 0.125   | 6.8  |
| Candida tropicalis (37) | Amphotericin B    | ≤0.5 to 1   | ≤0.5        | 1       | 0    |
|                      | Flucytosine       | ≤0.062 to 4 | ≤0.125     | 0.125   | 5.4  |
|                      | Fluconazole       | 0.25 to 64  | 1          | 2       | 29.7 |
|                      | Itraconazole      | ≤0.062 to 64| 0.125      | 0.25    | 40.5 |
|                      | Voriconazole      | ≤0.062 to > 8| ≤0.062 | 0.125   | 27.0 |
| Candida krusei (12)  | Amphotericin B    | ≤0.5 to 2   | ≤0.5        | 1       | 0    |
|                      | Flucytosine       | 2 to 8      | 4          | 8       | 0    |
|                      | Flucytosine       | –           | –          | –       | –    |
|                      | Itraconazole      | ≤0.062 to 4 | 0.125      | 0.5     | 33.4 |
|                      | Voriconazole      | ≤0.062 to > 8| ≤0.125  | 0.25    | 25.0 |
| Candida parapsilosis (5) | Amphotericin B    | ≤0.5 to 1   | ≤0.5        | 1       | 0    |
|                      | Flucytosine       | ≤0.062 to 0.5| 0.125    | 0.25    | 0    |
|                      | Fluconazole       | 0.25 to 16  | 0.5        | 2       | 20.0 |
|                      | Itraconazole      | ≤0.062 to 1 | ≤0.062     | 0.125   | 20.0 |
|                      | Voriconazole      | ≤0.062 to > 4| ≤0.062 | 0.125   | 20.0 |
| Others (6)           | Amphotericin B    | ≤0.5 to 1   | ≤0.5        | 1       | 0    |
|                      | Flucytosine       | ≤0.062 to 1 | ≤0.125     | 0.25    | 0    |
|                      | Fluconazole       | 0.5 to 64   | 1          | 4       | 16.7 |
|                      | Itraconazole      | ≤0.062 to 0.125| ≤0.062| 0.125   | 0    |
|                      | Voriconazole      | ≤0.062 to 0.5| ≤0.062 | 0.125   | 0    |
| All of isolates (243)| Amphotericin B    | –           | –          | –       | 0    |
|                      | Flucytosine       | –           | –          | –       | 4.1  |
|                      | Fluconazole       | –           | –          | –       | 18.6 |
|                      | Itraconazole      | –           | –          | –       | 23.1 |
|                      | Voriconazole      | –           | –          | –       | 18.5 |

**MIC** minimal inhibitory concentration

*a* Resistance rate was based on the intrinsic resistance of C. krusei and did not follow the actual MICs

*b* The breakpoints of Candida spp. according to the manufacturer’s instructions of ATB FUNGUS 3 system

*c* Others include C. guilliermondii (3), C. haemulonii (2) and C. pseudotropicalis (1)
per 1000 admissions), over the past 5 years [3]. However, the annual incidence of IC in our study (0.41 cases per 1000 admissions) was lower than those in metropolitan cities in China, such as Shanghai [26] (9.49 cases per 1000 admissions), and Nanjing [27] (0.71 to 0.85 cases per 1000 admissions). The reason for these different incidences might be that the subjects in Shanghai were mainly patients in ICUs wards, whereas the subjects in Nanjing were mainly patients with candidemia only.

In the study, *C. albicans* was the predominant species (50%) in the ICU. These results are consistent with a report from a multicenter prospective observational study in China [12]. However, in medical wards, the proportion of *C. glabrata* was higher than that of *C. albicans*, which was only exhibited in patients with hematological malignancies in the USA [28]. Although non-*C. albicans* species were significantly predominant, *C. albicans* was the most common isolate, consistent with reports from most other areas in China [26, 29–31]. However, in Nanjing [27], *C. tropicalis* was the most common isolate (28.6%). A possible reason may be related to the type of infection (only candidemia). In our study, we also found that *C. glabrata* was the second most common *Candida* species, similar to a report from a hospital in China [30], and hospitals in Denmark [32], Germany [33] and the USA [34]. Besides, we found that invasive *Candida* infections occurred more frequently in males of advanced age (age > 65), which was similar with those findings in USA [35], Denmark [32], Pakistan [10], China (Beijing) [30] and China (Nanjing) [27], however, the actual reasons for this finding are not fully understood. In those patients aged 50 to 65 years old, *C. glabrata* was the most common *Candida* species; this result was different from a 133 sample-based study in China [27].

With regard to resistance, resistance to FCA, ITR and VRC were common in *C. albicans* and non-*C. albicans* species. Our studies showed that the ITR resistance rate was the highest, at 23.1% in all *Candida* species, followed by FCA (18.6%), VRC (18.5%) and 5-FC (4.1%). However, none of the isolates in this study were resistant to AMB, and the susceptibility results in our city were higher than those in northern Ireland (susceptibility, 99.1%) [36]. In China, the resistance rates vary significantly among different cities. As shown in Table 5, the total resistance rates of all *Candida* species in the study were higher than those in metropolitan cities, especially Beijing [37] and Chongqing [38], which were higher than those in the China Survey of Candidiasis (China-SCAN) study [12]. Possible reasons may be related to the irrational use of antifungal agents, in healthcare and veterinary settings and by the general public [39]. In contrast, the resistance rates in our study were lower than those in Nanjing [27]. Regarding other countries, the antifungal resistance rate in our study was higher than that reported in northern Ireland in 2007–2011 [36]. The resistance rate of azoles in *C. albicans* (< 5%) [40] worldwide was significantly lower than that in our study (> 20.0%). The results of the ARTEMIS DISK Global Antifungal Surveillance Study showed that FCA- and VRC-resistant isolates of *C. glabrata* (15.7 and 10.0% resistance, respectively) [29] were approximately 1.5 times more prevalent than those in our study (11.0 and 6.8% resistance rates, respectively). The resistance rate of ITR in our study (23.1%) was higher than that in the USA (21.1%) [34]. The proportion of VRC-resistant isolates in our study was similar to that observed in India (18.5% vs 18.7%) [41]. In addition, our data showed that the resistance rates of FCA, ITR and VRC were higher...
Table 3 Factors associated with 30-day mortality by univariate analysis in patients with IC

| Variable                              | 30-day outcome | P-value |
|---------------------------------------|----------------|---------|
|                                       | Survived (n = 213) | Died (n = 30) |
| Age (years) (range)                   | 57.8(17–91)     | 62.7(29–81)     | 0.127 |
| Gender (male:female)                  | 124:89          | 15:15          | 0.394 |
| Underlying comorbidities (n, %)       |                |                |     |
| Gastrointestinal perforation          | 39 (18.3)       | 9 (30.0)       | 0.132 |
| Respiratory dysfunction               | 31 (14.6)       | 20 (66.7)      | < 0.001 |
| Pulmonary infection                   | 63 (29.6)       | 18 (60.0)      | 0.001 |
| Cardiovascular disease                | 58 (27.2)       | 20 (66.7)      | < 0.001 |
| Neurological diseases                 | 47 (22.1)       | 11 (36.7)      | 0.079 |
| Gastrointestinal pathology            | 56 (26.3)       | 7 (23.3)       | 0.729 |
| Chronic/acute liver disease           | 36 (16.9)       | 9 (30.0)       | 0.084 |
| Chronic/acute renal failure           | 74 (34.7)       | 16 (53.3)      | 0.048 |
| Solid tumour                          | 19 (8.9)        | 3 (10.0)       | 0.847 |
| Haematological malignancy             | 5 (2.3)         | 1 (3.3)        | 0.991 |
| Severe autoimmune diseases            | 8 (3.8)         | 3 (10.0)       | 0.124 |
| Diabetes mellitus                     | 79 (37.1)       | 14 (46.7)      | 0.312 |
| Burns                                 | 5 (2.3)         | 1 (3.3)        | 0.745 |
| HIV/AIDS                              | 11 (5.2)        | 2 (6.7)        | 0.732 |
| Severe trauma                         | 13 (6.1)        | 2 (6.7)        | 0.904 |
| Risk factors (n, %)                   |                |                |     |
| Presence of CVC                       | 104 (48.8)      | 14 (46.7)      | 0.825 |
| Mechanical ventilation                | 67 (31.5)       | 15 (50.0)      | 0.044 |
| Receipt of corticosteroids             | 58 (27.2)       | 12 (40.0)      | 0.148 |
| Total parenteral nutrition             | 100 (46.9)      | 19 (63.3)      | 0.093 |
| Chemotherapy                          | 10 (4.7)        | 1 (3.3)        | 0.737 |
| Abdominal surgery                     | 67 (31.5)       | 2 (6.7)        | 0.005 |
| In the ICU at diagnosis               | 30 (14.1)       | 12 (40.0)      | < 0.001 |
| Neutropenia                           | 5 (2.3)         | 2 (6.7)        | 0.185 |
| Concomitant bacterial infections       | 67 (31.5)       | 14 (46.7)      | 0.098 |
| Septic shock                          | 35 (16.4)       | 11 (36.7)      | 0.008 |
| Dialysis                              | 21 (9.9)        | 4 (13.3)       | 0.558 |
| Prior exposure to broad-spectrum      | 188 (88.3)      | 27 (90.0)      | 0.780 |
| antibiotics                            |                |                |     |
| Treatment with antifungal agents      | 71 (33.3)       | 12 (40.0)      | 0.471 |
| Species, n (%)                        |                |                |     |
| C. albicans                           | 90 (42.3)       | 20 (66.7)      | 0.012 |
| C. glabrata                            | 67 (31.5)       | 6 (20.0)       | 0.200 |
| C. tropicalis                          | 34 (16.0)       | 3 (10.0)       | 0.395 |

ICU intensive care unit, CVC central venous catheter

Table 4 Factors associated with 30-day mortality by multivariate analysis

| Variable                              | Odds ratio | 95% confidence interval | P-value |
|---------------------------------------|------------|-------------------------|---------|
| Respiratory dysfunction               | 9.80       | 3.24–29.63              | < 0.001 |
| Pulmonary infection                   | 1.09       | 0.39–3.06               | 0.871   |
| Cardiovascular disease                | 2.37       | 0.81–6.92               | 0.114   |
| Chronic/acute liver disease           | 0.61       | 0.18–2.06               | 0.426   |
| Chronic/acute renal failure           | 1.86       | 0.63–5.45               | 0.262   |
| Neurological diseases                 | 0.93       | 0.33–2.61               | 0.884   |
| Total parenteral nutrition            | 1.66       | 0.49–5.59               | 0.414   |
| Mechanical ventilation                | 0.71       | 0.19–2.68               | 0.617   |
| Abdominal surgery                     | 0.22       | 0.04–1.08               | 0.062   |
| In the ICU at diagnosis               | 2.22       | 0.70–6.89               | 0.176   |
| Concomitant bacterial infections      | 0.88       | 0.30–2.60               | 0.821   |
| Septic shock                          | 1.91       | 0.58–6.29               | 0.289   |
| C. albicans                           | 3.35       | 1.13–9.92               | 0.029   |

ICU intensive care unit

in 2013 than in 2014, but the resistance rate of isolates significantly increased in 2015. The percentages of yeast isolates with resistance and decreased susceptibility to FCA, ITR and VRC showed a significant decrease from 2015 to 2017 (Fig. 2). Moreover, the annual resistance rate of antifungal agents was associated with the usage frequency of antifungal agents (Fig. 2 and Table 6). Therefore, it is necessary to surveil the changes in the resistance rate of antifungal agents.

In this study, we analyzed the prognostic factors in patients with IC. Respiratory dysfunction, pulmonary infection, cardiovascular disease, chronic/acute renal failure, mechanical ventilation, abdominal surgery, intensive care in adults, septic shock and IC due to C. albicans were the predictors of mortality in the univariate analysis (P < 0.05). The number of prognostic factors (9 factors) in our city was clearly more than that in other regions of China, such as Beijing [3], Shanghai [26], Chongqing [38], Nanjing [27] and Jinan [4], and all the data are illustrated in the Additional file 2: Table S2. The differences in the prognostic factors in different cities might be related to the underlying diseases of patients in different cities, but the actual reasons are still unclear. Out of all the variables that were significantly associated with mortality in the univariate analysis, respiratory dysfunction and IC due to C. albicans were the predictive factors of mortality in the multivariate analysis. The results of some factors in this study agreed with the findings of a multicenter prospective observational study in China [31] and a retrospective analysis in Mexico [9]. In a study of critically ill patients, IC-associated mortality accounted for 58.6% [8]; the crude 30-day mortality rate
Table 5  The resistance rates of antifungal agents in different cities in China

| Species     | Antifungal agent | Beijing | Chongqing | Nanjing | China-SCAN study | Luzhou |
|-------------|------------------|---------|-----------|---------|------------------|--------|
| C. albicans | FCA              | 6.6     | 2.4       | 25.8    | 9.6              | 20.0   |
|             | VRC              | 2.9     | 5.6       | 0       | 0                | 23.6   |
|             | ITR              | 4.9     | 6.4       | 6.4     | 16.0             | 28.2   |
|             | 5-FC             | 2.4     |           |         |                  | 5.5    |
|             | AMB              | 0       |           | 0       |                  | 0      |
| C. glabrata | FCA              | 10.5    | 13.7      | 90.9    | 4.0              | 11.0   |
|             | VRC              | 9.1     | 0.0       | 6.0     | 6.8              | 6.8    |
|             | ITR              | 45.5    | 90.9      | 4.0     | 6.8              | 6.8    |
|             | 5-FC             | 3.0     |           | 2.7     |                  |        |
|             | AMB              | 0       |           | 0       |                  | 0      |
| C. tropicalis| FCA             | 10.6    | 2.2       | 68.4    | 6.0              | 29.7   |
|             | VRC              | 10.6    | 0.0       | 8.7     | 0                | 27.0   |
|             | ITR              | 0       | 34.2      | 31.3    | 40.5             |        |
|             | 5-FC             | 0       |           | 5.4     |                  |        |
|             | AMB              | 0       |           | 0       |                  | 0      |
| C. krusei  | FCA              | –       | –         | –       | –                | –      |
|             | VRC              | 0       | 0         | 0       | 25.0             |        |
|             | ITR              | 66.7    | 0         | 0       | 33.4             |        |
|             | 5-FC             | 0       |           | 0       |                  |        |
|             | AMB              | 0       |           | 0       |                  | 0      |
| C. parapsilosis | FCA        | 2.4     | 42.3      | 19.3    | 20.0             |        |
|             | VRC              | 0       | 0         | 36.0    | 20.0             |        |
|             | ITR              | 2.4     | 3.8       | 39.8    | 20.0             |        |
|             | 5-FC             | 0       |           | 0       |                  |        |
|             | AMB              | 0       |           | 0       |                  | 0      |
| Total FCA  |                  | 7.5     | 53.9      | 18.4    | 20.0             |        |
| Total VRC  |                  | 5.4     | 2.2       | 18.4    | 20.0             |        |
| Total ITR  |                  | 4.9     | 30.5      | 23.2    | 20.0             |        |
| Total 5-FC |                  | 0       | 0         | 0       | 20.0             |        |

| Species     | Antifungal agent | Beijing | Chongqing | Nanjing | China-SCAN study | Luzhou |
|-------------|------------------|---------|-----------|---------|------------------|--------|
| C. albicans | FCA              | 6.6     | 2.4       | 25.8    | 9.6              | 20.0   |
|             | VRC              | 2.9     | 5.6       | 0       | 0                | 23.6   |
|             | ITR              | 4.9     | 6.4       | 6.4     | 16.0             | 28.2   |
|             | 5-FC             | 2.4     |           |         |                  | 5.5    |
|             | AMB              | 0       |           | 0       |                  | 0      |
| C. glabrata | FCA              | 10.5    | 13.7      | 90.9    | 4.0              | 11.0   |
|             | VRC              | 9.1     | 0.0       | 6.0     | 6.8              | 6.8    |
|             | ITR              | 45.5    | 90.9      | 4.0     | 6.8              | 6.8    |
|             | 5-FC             | 3.0     |           | 2.7     |                  |        |
|             | AMB              | 0       |           | 0       |                  | 0      |
| C. tropicalis| FCA             | 10.6    | 2.2       | 68.4    | 6.0              | 29.7   |
|             | VRC              | 10.6    | 0.0       | 8.7     | 0                | 27.0   |
|             | ITR              | 0       | 34.2      | 31.3    | 40.5             |        |
|             | 5-FC             | 0       |           | 5.4     |                  |        |
|             | AMB              | 0       |           | 0       |                  | 0      |
| C. krusei  | FCA              | –       | –         | –       | –                | –      |
|             | VRC              | 0       | 0         | 0       | 25.0             |        |
|             | ITR              | 66.7    | 0         | 0       | 33.4             |        |
|             | 5-FC             | 0       |           | 0       |                  |        |
|             | AMB              | 0       |           | 0       |                  | 0      |
| C. parapsilosis | FCA        | 2.4     | 42.3      | 19.3    | 20.0             |        |
|             | VRC              | 0       | 0         | 36.0    | 20.0             |        |
|             | ITR              | 2.4     | 3.8       | 39.8    | 20.0             |        |
|             | 5-FC             | 0       |           | 0       |                  |        |
|             | AMB              | 0       |           | 0       |                  | 0      |
| Total FCA  |                  | 7.5     | 53.9      | 18.4    | 20.0             |        |
| Total VRC  |                  | 5.4     | 2.2       | 18.4    | 20.0             |        |
| Total ITR  |                  | 4.9     | 30.5      | 23.2    | 20.0             |        |
| Total 5-FC |                  | 0       | 0         | 0       | 20.0             |        |

FCA fluconazole, ITR itraconazole, AMB amphotericin B, VRC voriconazole, 5-FC flucytosine

Table 6  The frequencies of antifungal usage in patients from 2013 to 2017

| Antifungal agent | Patients n (%) |
|------------------|----------------|
|                  | Total (n = 243) | 2013 (n = 20) | 2014 (n = 29) | 2015 (n = 44) | 2016 (n = 74) | 2017 (n = 76) |
| Amphotericin B(i.v.) | 49 (20.2) | 6 (30.0%) | 5 (17.2) | 13 (29.5) | 17 (23.0) | 8 (10.5) |
| Fluconazole(i.v.) | 122 (52.8) | 11 (55.0%) | 20 (69.0) | 19 (43.2) | 30 (40.5) | 42 (55.3) |
| Voriconazole(i.v.) | 84 (34.6) | 8 (40.0%) | 10 (34.5) | 15 (34.1) | 27 (36.5) | 24 (31.6) |
| other** | 20 (13.3) | 0 | 0 | 0 | 15 (20.3) | 5 (6.5) |

i.v. intravenous  
**C. krusei is excluded  
other including caspofungin (intravenous) and itraconazole (oral)  
*Some patients used more than two kind of antifungal drugs during the course of treatment
in our study was only 12.3% in all patients with IC, which was substantially lower than the mortality rates reported in Italy (42.8%) [42], Mexico (38%) [9], Pakistan (52.1%) [10], Spain (30.0%) [43], Jinan (23.1%,China) [4] and Nanjing (26.0%,China) [27]. The reason for the high mortality rate might be that the research subjects in those countries and cities were mainly ICU-patients or patients with candidaemia. Those cases often had more severe underlying diseases and conditions, which are associated with high mortality, therefore having a higher risk of mortality [44, 45]. Conversely, the percentages of ICU patient and patient with candidaemia in our study were only accounted for 17.3 and 47.7%, respectively. The lower mortality rate in our study was also identified in the Pu, S, et al. [38] with similar subjects in Chongqing. In our study, the mortality rate due to C. haemulonii was the highest (50%, 1/2), possibly because there were only two cases. The fatal case in our study was a critically ill patient in the ICU with respiratory dysfunction and severe underlying comorbidities. Excluding C. haemulonii, C. albicans was associated with the highest mortality rate (18.2%). In our study, respiratory dysfunction was the major cause of mortality (39.2%) in patients (OR, 9.80; 95% CI, 3.24–29.63; P < 0.001); Meanwhile, another study also indicated that hematological malignancy was also an independent predictor for 66.7% of death of in-hospital patients [27]. Certainly, the severity of the underlying comorbidities (hematological malignancy and respiratory dysfunction) considerably influenced the crude mortality rate in this patient population.

This study has several potential limitations. First, the subjects in our study were restricted to adult patients (>16 years old). Therefore, our conclusions may not be extrapolated to pediatric patients. Second, due to the technical limitations of the clinical microbiology laboratory and the impact of hospital policies, there are no data on echinocandins in our hospital. Finally, this was a single-center retrospective study. Our data might be influenced by the distribution of the regional population, the level of medical intervention, and the distribution of patient types.

Conclusion
This study shows that the incidence and mortality of IC in medium and small cities are lower than those in large cities, that the resistance rate to azoles is higher in medium and small cities than in large cities, and that the species distribution and risk factors in medium and small cities are different from those in large cities in China. This study provides reference data for future epidemiological and susceptibility studies on both antifungal agents and mortality due to IC in our hospital and in other hospitals in medium and small cities.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12879-019-4588-9.

Additional file 1: Table S1. The different of urban population proportion, GDP, income, education resources, sports resources, medical resources and air population between Luzhou city and other cities in 2013.

Additional file 2: Table S2. The difference of prognostic factors in difference studies about invasive candidiasis

Abbreviations
S-FC: flucytosine; AMB: Amphotericin B; CI: Confidence Interval; CVC: Central venous catheter; FCA: Fluconazole; IC: Invasive candidiasis; ICU: Intensive care unit; IFD: Invasive fungal disease; ITR: Itraconazole; MALDI-TOF MS: Matrix-assisted laser desorption/ionization-time of flight mass spectroscopy; MIC: Minimal inhibitory concentration; OR: Odds ratio; VRC: Voriconazole

Acknowledgements
We thank Yanhan Li in the medical records room for guiding us in reviewing the electronic medical records. We have asked for American Journal Experts (AJE, www.aje.com) for its linguistic assistance during the preparation of this revised manuscript.

Authors’ contributions
ZRZ, GT and JD designed the study and drafted the manuscript. ZRZ, YHD, AJF, ZY, ZL, YS, ZWN and JD analyzed the data, ZRZ wrote the paper, ZRZ and JD contributed equally to this work and share first authorship. All authors have read approved the final manuscript.

Funding
This work was supported by the Science and Technology Project of Health and Family Planning Commission of Sichuan Province (No. 17PJ506), Luzhou Medical College Science Foundation (No. 2014QN-048) and the Affiliated Hospital of Luzhou Medical College Science Foundation (No. 15063). The funder had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University (project no. K2016004). This is a retrospective study. The need for informed consent was waived by the Clinical Research Ethics Committee.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 14 March 2019 Accepted: 22 October 2019
Published online: 07 November 2019

References
1. Kullberg BJ, Atendrup MC. Invasive Candidiasis. N Engl J Med. 2015;373(15):1445–56.
2. McCarty TP, Pappas PG. Invasive Candidiasis. Infect Dis Clin N Am. 2016; 30(1):103–24.
3. Wang L, Tong Z, Wang Z, Xu L, Wu Y, Liu Y, Wu L. Single-center retrospective study of the incidence of, and risk factors for, non-C. albicans invasive candidiasis in hospitalized patients in China. Med Mycol. 2014;52(2):115–22. doi:10.1111/med.12187.
4. Wang H, Liu N, Yin M, Han H, Yue J, Zhang F, Shan T, Guo H, Wu D. The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study. BMC Infect Dis. 2014;14:609.
5. Kakey H, Yamada K, Kaneko Y, Yanagihara K, Tateda K, Maesaki S, Takeuchi Y, Tomono K, Kodota JI, Kaku M, et al. National Trends in the distribution of Candida species causing Candidemia in Japan from 2003 to 2014. Med Mycol. 2018;56(1):19–22.

6. Mencarini J, Mantengoli E, Tofani L, Riccobono E, Fornari R, Bartalesi F, Corti G, Faere A, Pecile P, Boni L, et al. Evaluation of candidemia and antifungal consumption in a large tertiary care Italian hospital over a 12-year period. Infection. 2018;46(4):469–76.

7. Vasilyeva NV, Raush ER, Rudneva MV, Bogomolova TS, Taraskina AE, Fang Y, Zhan F, Klimko TN. Etiology of invasive candidosis agents in Russia: a multicenter epidemiological survey. Front Med. 2018;12(1):84–91.

8. Al-Dorzi HM, Sakkijha H, Khan R, AlDabbagh T, Toledo A, Ntinika P, Al Johani SM, Bao YM. Invasive candidiasis in critically ill patients: a prospective cohort study in two tertiary care centers. J Intensive Care. 2018. https://doi.org/10.1186/s40560-016-0783-5 (PubMed PMID: 29628014).

9. Gonzalez-Lara MF, Torres-Gonzalez P, Cornejo-Juarez P, Velazquez-Acosta C, Martinez-Gamboa A, Rangel-Cordero A, Bobadilla-Del-Valle M, Ostrosky-Zeichner L, Ponce-de-Leon A, Silfentres-Domisco J. Impact of inappropriate antifungal therapy according to current susceptibility breakpoints of Candida bloodstream infection mortality: a retrospective analysis. BMC Infect Dis. 2017;17(1):753.

10. Farooqi JQ, Jabeen K, Saeed N, Iqbal N, Malik B, Lockhart SR, Zafar A, Brandt ME, Hasan R. Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility. J Med Microbiol. 2013;62(2):259–68.

11. Falagas ME, Rousou N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14(1):e95–64.

12. Guo F, Yang Y, Kang Y, Zang B, Cui W, Qin B, Qin Y, Fang Q, Qin T, Jiang D, et al. Invasive candidiasis in intensive care units in China: a multicenter prospective observational study. J Antimicrob Chemother. 2013;68(1):1660–8.

13. Xie GH, Fang XM, Fang Q, Wu XM, Jin YH, Wang JL, Guo QL, Gu MN, Xu QP, Wang DX, et al. Impact of antifungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients. Crit Care. 2008;12(1):R5.

14. Chen M, Xu Y, Hong N, Yang Y, Lei W, Du L, Zhao J, Lei X, Xiong L, Cai L, et al. Epidemiology of fungal infections in China. Front Med. 2018;12(1):58–75.

15. Xiao M, Sun ZY, Kang M, Guo DW, Liao K, Chen SC, Kong F, Fan X, Cheng JW, Hou X, et al. Five-year National Surveillance of invasive candidiasis: species distribution andazole susceptibility from the China hospital invasive fungal surveillance net (CHIF-NET) study. J Clin Microbiol. 2018;56(7):e00577–18.

16. Liu W, Tan J, Sun J, Xu Z, Li M, Yang Q, Shao H, Zhang L, Liu W, Wan Z, et al. Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility of Candida bloodstream infection isolates. Chin J Mycol. 2016;5(4):897–700. http://www.emedicine.org.cn/CN112138200608/039329.htm.

17. Chinese Society of Respiratory Diseases, Editorial Board of Chinese Journal of Tuberculosis and Respiratory Diseases. Consensus on the diagnosis and treatment of invasive pulmonary mycosis. Chin J Intern Med. 2006;45(8):697–700. http://www.emedicine.org.cn/CN112138200608/039329.htm.

18. Chinese Society of Respiratory Diseases, Editorial Board of Chinese Journal of Tuberculosis and Respiratory Diseases: Consensus on the diagnosis and treatment of invasive pulmonary mycosis. Chin J Tuberc Respir Dis 2007, 30(1):821–834. http://www.cnki.net/journals/jbehe/20070301898.htm

19. Society of Critical Care Medicine CMA. Guidelines for the diagnosis and treatment of invasive fungal infections in critically ill patients (2007). Chin J Intern Med. 2007;46(1):960–6. http://www.emedicine.org.cn/CN112138200713/395604.htm.

20. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Muerheo J, Lortholary O, Kaufman CA, et al. Revised definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer/Invasive fungal infections Cooperative Group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813–21.

21. Merritt LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sheerzzi RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45.

22. Wei QJ, Shenghe LL, Jin HR. Applicability of the new standard of city-size classification in China. Progress Geographic. 2016;35(1):47–56. https://doi.org/10.18306/jdgdx.2016.01.006.
44. Huppler AR, Fisher BT, Lehmbacher T, Walsh TJ, Steinbach WJ. Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children. J Pediatric Infect Dis Soc. 2017;6(suppl_1):S32–44.

45. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(suppl_1):i4–i13.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.